{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:33:08Z","timestamp":1787772788298,"version":"build-2784847793"},"reference-count":46,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Conversion surgery, defined as surgical resection with curative intent after a favorable response to systemic chemotherapy in patients with initially unresectable gastric cancer, has attracted considerable attention as a potential treatment strategy for metastatic disease. Observational studies suggest that long-term survival may be achieved when R0 resection is accomplished. However, the therapeutic landscape has changed with advances in systemic treatment, including immune checkpoint inhibitor\u2013based regimens. Recent evidence indicates that some patients who respond well to modern systemic therapies may achieve prolonged survival without surgery. Emerging observational data also suggest that, among patients with profound tumor regression or complete response to chemotherapy, overall survival may not differ substantially between those undergoing surgery and those continuing systemic therapy alone, raising important questions regarding the necessity of conversion surgery in current clinical practice. Accordingly, the Japanese Gastric Cancer Treatment Guidelines 2025 concluded that evidence remains insufficient to make a clear recommendation regarding conversion surgery. This review summarizes the concept and definition of conversion surgery, outlines the resectability classifications proposed by the Japan Clinical Oncology Group, and critically reviews evidence from observational studies and prospective trials, with particular attention to chemotherapy responders treated with or without surgery. In the modern treatment era, conversion surgery remains a promising approach; however, whether it offers a survival advantage over continued systemic chemotherapy has not been established. Clarification of its appropriate role in metastatic gastric cancer requires evidence from prospective randomized trials.<\/jats:p>","DOI":"10.1093\/jjco\/hyag137","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T11:16:38Z","timestamp":1786101398000},"source":"Crossref","is-referenced-by-count":0,"title":["Conversion surgery for gastric cancer: current status and future perspectives"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5245-7502","authenticated-orcid":false,"given":"Itaru","family":"Yasufuku","sequence":"first","affiliation":[{"name":"Department of Clinical Anatomy Development Studies, Gifu University Graduate School of Medicine , 501-1194 Yanagito 1-1, Gifu-City, Gifu ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Okuma","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological and Pediatric Surgery, Gifu University Graduate School of Medicine , 501-1194 Yanagito 1-1, Gifu-City, Gifu ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syunpei","family":"Tonomura","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological and Pediatric Surgery, Gifu University Graduate School of Medicine , 501-1194 Yanagito 1-1, Gifu-City, Gifu ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seito","family":"Fujibayashi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological and Pediatric Surgery, Gifu University Graduate School of Medicine , 501-1194 Yanagito 1-1, Gifu-City, Gifu ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wakana","family":"Chikaishi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological and Pediatric Surgery, Gifu University Graduate School of Medicine , 501-1194 Yanagito 1-1, Gifu-City, Gifu ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahide","family":"Endo","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological and Pediatric Surgery, Gifu University Graduate School of Medicine , 501-1194 Yanagito 1-1, Gifu-City, Gifu ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Hatanaka","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological and Pediatric Surgery, Gifu University Graduate School of Medicine , 501-1194 Yanagito 1-1, Gifu-City, Gifu ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Fukada","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological and Pediatric Surgery, Gifu University Graduate School of Medicine , 501-1194 Yanagito 1-1, Gifu-City, Gifu ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuichi","family":"Asai","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological and Pediatric Surgery, Gifu University Graduate School of Medicine , 501-1194 Yanagito 1-1, Gifu-City, Gifu ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological and Pediatric Surgery, Gifu University Graduate School of Medicine , 501-1194 Yanagito 1-1, Gifu-City, Gifu ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse Yu","family":"Tajima","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological and Pediatric Surgery, Gifu University Graduate School of Medicine , 501-1194 Yanagito 1-1, Gifu-City, Gifu ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akitaka","family":"Makiyama","sequence":"additional","affiliation":[{"name":"Cancer Center, Gifu University Hospital , 501-1194 Yanagito 1-1, Gifu-City, Gifu ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological and Pediatric Surgery, Gifu University Graduate School of Medicine , 501-1194 Yanagito 1-1, Gifu-City, Gifu ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhisa","family":"Matsuhashi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological and Pediatric Surgery, Gifu University Graduate School of Medicine , 501-1194 Yanagito 1-1, Gifu-City, Gifu ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"key":"2026082615074946800_ref1","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","article-title":"Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Lordick","year":"2022","journal-title":"Ann Oncol"},{"key":"2026082615074946800_ref2","doi-asserted-by":"publisher","first-page":"102226","DOI":"10.1016\/j.esmoop.2023.102226","article-title":"Pan-Asian adapted ESMO clinical practice guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer","volume":"9","author":"Shitara","year":"2024","journal-title":"ESMO Open"},{"key":"2026082615074946800_ref3","doi-asserted-by":"crossref","first-page":"169","DOI":"10.6004\/jnccn.2025.0022","article-title":"Gastric cancer, version 2.2025, NCCN clinical practice guidelines in oncology","volume":"23","author":"Ajani","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"key":"2026082615074946800_ref4","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S1470-2045(15)00553-7","article-title":"Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial","volume":"17","author":"Fujitani","year":"2016","journal-title":"Lancet Oncol"},{"key":"2026082615074946800_ref5","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s10120-015-0575-z","article-title":"Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification","volume":"19","author":"Yoshida","year":"2016","journal-title":"Gastric Cancer"},{"key":"2026082615074946800_ref6","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.ijsu.2018.04.016","article-title":"Conversion surgery for gastric cancer: a cohort study from a western center","volume":"53","author":"Morgagni","year":"2018","journal-title":"Int J Surg"},{"key":"2026082615074946800_ref7","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s10120-017-0738-1","article-title":"The long-term survival of stage IV gastric cancer patients with conversion therapy","volume":"21","author":"Yamaguchi","year":"2018","journal-title":"Gastric Cancer"},{"key":"2026082615074946800_ref8","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1007\/s10120-019-00968-2","article-title":"Conversion gastrectomy for stage IV unresectable gastric cancer: a GIRCG retrospective cohort study","volume":"22","author":"Solaini","year":"2019","journal-title":"Gastric Cancer"},{"key":"2026082615074946800_ref9","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/ags3.12515","article-title":"International retrospective cohort study of conversion therapy for stage IV gastric cancer 1 (CONVO-GC-1)","volume":"6","author":"Yoshida","year":"2021","journal-title":"Annals of Gastroenterological Surgery"},{"key":"2026082615074946800_ref10","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1007\/s00595-022-02515-6","article-title":"A prognostic scoring system for conversion surgery after trastuzumab-based chemotherapy for human epidermal growth factor receptor 2-positive advanced gastric cancer","volume":"52","author":"Arigami","year":"2022","journal-title":"Surg Today"},{"key":"2026082615074946800_ref11","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s10120-025-01683-x","article-title":"Safety, survival outcomes, and prognostic factors in conversion surgery for advanced gastric cancer: a sub-analysis of Japanese patients in the CONVO-GC-1 study","volume":"29","author":"Yasufuku","year":"2026","journal-title":"Gastric Cancer"},{"key":"2026082615074946800_ref12","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s10120-025-01698-4","article-title":"Japanese gastric cancer treatment guidelines 2025 (7th edition)","volume":"29","year":"2026","journal-title":"Gastric Cancer"},{"key":"2026082615074946800_ref13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"2026082615074946800_ref14","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S1470-2045(21)00692-6","article-title":"Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Kang","year":"2022","journal-title":"Lancet Oncol"},{"key":"2026082615074946800_ref15","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial","volume":"24","author":"Rha","year":"2023","journal-title":"Lancet Oncol"},{"key":"2026082615074946800_ref16","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1056\/NEJMc2408121","article-title":"Pembrolizumab in HER2-positive gastric cancer","volume":"391","author":"Janjigian","year":"2024","journal-title":"N Engl J Med"},{"key":"2026082615074946800_ref17","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","article-title":"Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial","volume":"29","author":"Shah","year":"2023","journal-title":"Nat Med"},{"key":"2026082615074946800_ref18","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","article-title":"Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial","volume":"401","author":"Shitara","year":"2023","journal-title":"Lancet"},{"key":"2026082615074946800_ref19","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1002\/bjs.9484","article-title":"Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with Para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis","volume":"101","author":"Tsuburaya","year":"2014","journal-title":"Br J Surg"},{"key":"2026082615074946800_ref20","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1007\/s10120-016-0619-z","article-title":"A phase II study of preoperative chemotherapy with docetaxel, cisplatin, and S-1 followed by gastrectomy with D2 plus Para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis: JCOG1002","volume":"20","author":"Ito","year":"2017","journal-title":"Gastric Cancer"},{"key":"2026082615074946800_ref21","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1007\/s10120-023-01453-7","article-title":"Short-term outcomes of preoperative chemotherapy with docetaxel, oxaliplatin, and S-1 for gastric cancer with extensive lymph node metastasis (JCOG1704)","volume":"27","author":"Kurokawa","year":"2024","journal-title":"Gastric Cancer"},{"key":"2026082615074946800_ref22","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1186\/s12885-017-3918-9","article-title":"The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction\u2014a phase III trial of the German AIO\/CAO-V\/CAOGI","volume":"17","author":"Al-Batran","year":"2017","journal-title":"BMC Cancer"},{"key":"2026082615074946800_ref23","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1001\/jamaoncol.2017.0515","article-title":"Effect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction cancer: the AIO-FLOT3 trial","volume":"3","author":"Al-Batran","year":"2017","journal-title":"JAMA Oncol"},{"key":"2026082615074946800_ref24","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.7314\/APJCP.2015.16.4.1665","article-title":"Outcome after simultaneous resection of gastric primary tumour and synchronous liver metastases: survival analysis of a single-center experience in China","volume":"16","author":"Liu","year":"2015","journal-title":"Asian Pac J Cancer Prev"},{"key":"2026082615074946800_ref25","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1002\/jso.23920","article-title":"Hepatic resection for gastric cancer liver metastases: a systematic review and meta-analysis","volume":"111","author":"Petrelli","year":"2015","journal-title":"J Surg Oncol"},{"key":"2026082615074946800_ref26","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1097\/SLA.0000000000001542","article-title":"Influence of surgical resection of hepatic metastases from gastric adenocarcinoma on long-term survival: systematic review and pooled analysis","volume":"263","author":"Markar","year":"2016","journal-title":"Ann Surg"},{"key":"2026082615074946800_ref27","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1007\/s10120-015-0530-z","article-title":"Surgical treatment of liver metastasis of gastric cancer: a retrospective multicenter cohort study (KSCC1302)","volume":"19","author":"Oki","year":"2016","journal-title":"Gastric Cancer"},{"key":"2026082615074946800_ref28","doi-asserted-by":"publisher","first-page":"103313","DOI":"10.1016\/j.critrevonc.2021.103313","article-title":"Surgical treatment of gastric cancer liver metastases: systematic review and meta-analysis of long-term outcomes and prognostic factors","volume":"163","author":"Granieri","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"2026082615074946800_ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.115080","article-title":"Prospective single-arm multicenter interventional study of surgical resection for liver metastasis from gastric cancer; 3-year overall and recurrence-free survival","volume":"213","author":"Fujitani","year":"2024","journal-title":"Eur J Cancer"},{"key":"2026082615074946800_ref30","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1007\/s10120-017-0730-9","article-title":"Role of hepatectomy in gastric cancer with multiple liver-limited metastases","volume":"21","author":"Shirasu","year":"2018","journal-title":"Gastric Cancer"},{"key":"2026082615074946800_ref31","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1245\/s10434-021-10750-3","article-title":"Prospective Multicenter interventional study of surgical resection for liver metastasis from gastric cancer: R0 resection rate, and operative morbidity and mortality","volume":"29","author":"Fujitani","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"2026082615074946800_ref32","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1007\/s10120-024-01467-9","article-title":"Early endpoints of a randomized phase II trial of preoperative chemotherapy with S-1\/CDDP with or without trastuzumab followed by surgery for HER2-positive resectable gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan clinical oncology group study JCOG1301C (trigger study)","volume":"27","author":"Tokunaga","year":"2024","journal-title":"Gastric Cancer"},{"key":"2026082615074946800_ref33","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1016\/j.ejso.2009.03.003","article-title":"A phase II study of radical surgery followed by postoperative chemotherapy with S-1 for gastric carcinoma with free cancer cells in the peritoneal cavity (CCOG0301 study)","volume":"35","author":"Kodera","year":"2009","journal-title":"Eur J Surg Oncol"},{"key":"2026082615074946800_ref34","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s10120-012-0156-3","article-title":"Long-term follow up of patients who were positive for peritoneal lavage cytology: final report from the CCOG0301 study","volume":"15","author":"Kodera","year":"2012","journal-title":"Gastric Cancer"},{"key":"2026082615074946800_ref35","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1245\/s10434-019-07697-x","article-title":"Efficacy of postoperative chemotherapy after resection that leaves No macroscopically visible disease of gastric cancer with positive peritoneal lavage cytology (CY1) or localized peritoneum metastasis (P1a): a Multicenter retrospective study","volume":"27","author":"Yamaguchi","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"2026082615074946800_ref36","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1200\/JCO.2018.77.8613","article-title":"Phase III trial comparing intraperitoneal and intravenous paclitaxel plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis: PHOENIX-GC trial","volume":"36","author":"Ishigami","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026082615074946800_ref37","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyad149","article-title":"Randomized controlled phase III study comparing chemotherapy alone versus conversion surgery after a remarkable response to chemotherapy in patients with initially unresectable cStage IVB or pStage IV gastric cancer (JCOG2301, conversion study)","volume":"55","author":"Kita","year":"2025","journal-title":"Jpn J Clin Oncol"},{"key":"2026082615074946800_ref38","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1200\/JCO.2025.43.4_suppl.402","article-title":"Short- and long-term outcomes of conversion surgery for initially unresectable advanced gastric cancer: a Japanese multicenter retrospective cohort study","volume":"43","author":"Yasufuku","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026082615074946800_ref39","doi-asserted-by":"publisher","first-page":"102301","DOI":"10.1016\/j.gassur.2025.102301","article-title":"A single-center retrospective study of conversion surgery in stage IV gastric cancer: association with immune checkpoint inhibitor-based chemotherapy","volume":"30","author":"Ushimaru","year":"2026","journal-title":"J Gastrointest Surg"},{"key":"2026082615074946800_ref40","doi-asserted-by":"publisher","first-page":"9023","DOI":"10.1245\/s10434-024-16161-4","article-title":"Conversion surgery after chemotherapy plus nivolumab as the first-line treatment for unresectable advanced or recurrent gastric cancer and a biomarker study using the Gustave Roussy immune score: a Multicenter study","volume":"31","author":"Nakazawa","year":"2024","journal-title":"Ann Surg Oncol"},{"key":"2026082615074946800_ref41","article-title":"First-line nivolumab plus chemotherapy vs chemotherapy for advanced gastric cancer\/gastroesophageal junction cancer\/esophageal adenocarcinoma: survival analyses by tumor response from CheckMate 649","author":"Kensei"},{"key":"2026082615074946800_ref42","doi-asserted-by":"publisher","first-page":"31169","DOI":"10.18632\/oncotarget.16099","article-title":"Depth of response is a significant predictor for long-term outcome in advanced gastric cancer patients treated with trastuzumab","volume":"8","author":"Lee","year":"2017","journal-title":"Oncotarget"},{"key":"2026082615074946800_ref43","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s10120-017-0729-2","article-title":"Associations between early tumor shrinkage and depth of response and clinical outcomes in patients treated with 1st-line chemotherapy for advanced gastric cancer","volume":"21","author":"Osumi","year":"2018","journal-title":"Gastric Cancer"},{"key":"2026082615074946800_ref44","article-title":"First-line nivolumab plus chemotherapy vs chemotherapy for advanced gastric cancer\/gastroesophageal junction cancer\/esophageal adenocarcinoma: 5-year follow-up of CheckMate 649","author":"Kensei"},{"key":"2026082615074946800_ref45","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1245\/s10434-025-18641-7","article-title":"Is surgery necessary for stage IVB gastric cancer showing clinical complete response to chemotherapy or systemic cancer therapy?","volume":"33","author":"Habu","year":"2025","journal-title":"Ann Surg Oncol"},{"key":"2026082615074946800_ref46","doi-asserted-by":"publisher","first-page":"LBA4001","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA4001","article-title":"Effect of chemotherapy\/targeted therapy alone vs. chemotherapy\/targeted therapy followed by radical surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction \u2013 the IKF-575 \/ RENAISSANCE phase III trial","volume":"42","author":"Al-Batran","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/advance-article-pdf\/doi\/10.1093\/jjco\/hyag137\/70808813\/hyag137.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/advance-article-pdf\/doi\/10.1093\/jjco\/hyag137\/70808813\/hyag137.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:12:35Z","timestamp":1787771555000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/advance-article\/doi\/10.1093\/jjco\/hyag137\/8771350"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":46,"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyag137","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]},"article-number":"hyag137"}}